Astellas Pharma Inc.-Unsp ADRALPMY
13F holders, Q2 2026 (June 30)7holders
1new positions
1sold out
$13.39avg. 13F price*
At the end of Q2 2026, 7 institutions reported holding Astellas Pharma Inc.-Unsp ADR (ALPMY) in their 13F filings, unchanged from Q1 2026. 1 opened new positions and 1 sold out. The largest holders were Hantz Financial Services, Inc. ($2.5M), Rhumbline Advisers ($289K) and GAMMA Investing LLC ($166K).
- Company
- Astellas Pharma Inc.-Unsp ADR
- CUSIP
- 04623U102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $17K |
| Exits | 1 | $710K |
All 13F filers, Q1 2026 → Q2 2026: 1,292 shares bought and 58,423 shares sold, net −57,131 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Hantz Financial Services, Inc. | 0.03% | Reduce -5.7% | 189,328 | $2.5M |
| Rhumbline Advisers | 0.00% | Reduce -0.7% | 21,642 | $289K |
| GAMMA Investing LLC | 0.01% | Reduce -2.6% | 12,434 | $166K |
| Wellington-Altus USA Inc. | 0.02% | No change | 2,017 | $32K |
| First Command Advisory Services, Inc. | 0.00% | New | 1,278 | $17K |
| Salomon & Ludwin, LLC | 0.00% | Reduce -69.8% | 734 | $10K |
| PNC Financial Services Group, Inc. | 0.00% | Add +25.0% | 70 | $936 |
"% of holder's portfolio" is ALPMY's weight in each manager's 13F, not the share of Astellas Pharma Inc.-Unsp ADR the manager owns.